Health and Healthcare

Neurocrine Bio Stumbles on Tourette Study Results

Neurocrine Biosciences Inc. (NASDAQ: NBIX) shares dipped on Wednesday after the company announced that its midstage Tourette syndrome study did not live up to expectations.

Specifically, the firm announced topline data from its Phase 2b T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale (YGTSS) in children and adolescents with moderate to severe Tourette syndrome.

The primary endpoint of T-Force GOLD was the change from baseline of the YGTSS Total Tic Score at week 12. The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity and interference.

Separately, the types of treatment emergent adverse events observed in this trial were consistent with those seen in other valbenazine studies.

Kevin Gorman, Ph.D., CEO at Neurocrine Biosciences, commented:

We are very disappointed with the topline data from the T-Force GOLD study given that children and adolescents with Tourette syndrome need better treatment options. This study was well-conducted with a placebo response as expected, but the treatment effect of valbenazine was lower than we had anticipated. We would like to thank the patients, caregivers and investigators for their participation in this study. We will further analyze the data to determine the next steps for valbenazine in Tourette syndrome.

Shares of Neurocrine Bio were last seen down about 22% at $66.81, in a 52-week range of $64.72 to $126.98. The consensus analyst price target is $130.27.

ALERT: Take This Retirement Quiz Now  (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.